Xuanzhu Biopharmaceutical Receives Stock Exchange Approval for H Share Full Circulation

Xuanzhu Biopharmaceutical Co., Ltd. (Stock Code: 2575) has released a significant announcement that is likely to draw the attention of investors and shareholders. The company has obtained approval from The Stock Exchange of Hong Kong Limited (HKEX) for its application to implement the full circulation of H Shares, a development that could have a material impact on the company’s share price and liquidity.

Key Points of the Announcement

• Approval Granted: On April 16, 2026, the HKEX approved the listing and permission to deal in 357,245,794 H Shares. These shares are being converted from unlisted shares as part of the company’s “H Share Full Circulation” plan.
• Conditions Outstanding: The approval is subject to the fulfilment of all other conditions required for the conversion and listing process.
• Listing to Involve Six Shareholders: The conversion affects six participating shareholders, who together hold the 357,245,794 unlisted shares (representing approximately 68.97% of the company’s total issued share capital).
• Post-Conversion Share Structure: Upon completion, all of the company’s shares will be listed H Shares, significantly increasing the free float and potentially enhancing liquidity and trading volume.

Details of Participating Shareholders and Shareholdings

The total number of shares involved in the conversion is 357,245,794, representing 68.97% of the company’s total issued share capital.

Changes in Shareholding Structure

• Before Conversion: The company had 357,245,794 unlisted shares (68.97%) and 160,701,996 H Shares (31.03%).
• After Conversion: All 517,947,790 shares will become H Shares, representing 100% of the total share capital.

This move will effectively eliminate the unlisted share class, making all shares tradable on the HKEX and potentially increasing market liquidity and transparency.

Potential Price-Sensitive Implications for Shareholders

• Potential Increase in Liquidity: The substantial rise in the number of H Shares in circulation could attract new investors, improve trading volume, and reduce the discount (if any) between H Shares and unlisted shares.
• Possible Share Price Volatility: The influx of a large number of shares onto the market could result in short-term share price volatility as the market digests the increased supply.
• Control and Ownership: Six major shareholders will have their previously unlisted shares converted, but their substantial holdings may remain a key factor in company governance.
• Further Announcements Expected: The company will provide additional updates as the conversion and listing process progresses, as required under the Listing Rules and Inside Information Provisions.
• Shareholder Advisory: The company advises shareholders and potential investors to exercise caution when dealing in the shares during this period of transition.

Company Leadership and Governance

The Board is chaired by Ms. Xu Yanjun, with a mix of executive, non-executive, and independent non-executive directors providing oversight.

Conclusion

The approval for H Share Full Circulation is a pivotal development for Xuanzhu Biopharmaceutical. By converting all unlisted shares into H Shares, the company is set to significantly increase its free float, improve market liquidity, and potentially attract a broader investor base. While these changes can offer long-term benefits, shareholders should remain vigilant regarding potential share price fluctuations during the transition.

Disclaimer: The contents of this article are based on public disclosures by Xuanzhu Biopharmaceutical Co., Ltd. and are intended for informational purposes only. This does not constitute investment advice. Investors should consult their financial advisors before making investment decisions and exercise caution in light of potential share price volatility.

View XUANZHUBIO-B Historical chart here